30 Jan 2026
Creo Medical Group - Delivering revenue growth
Creo provided a FY25 trading update with 50% revenue growth and strong operating cost containment, resulting in more than 40% reduction to the underlying operating loss. Broadly, increased adoption by new users and greater utilisation by existing users had driven revenue growth, with the company noting positive trends for the recently launched Speedboat Notch and SpydrBlade Flex device. Creo closed FY25 with cash of £12.4m. This updated supports our positive view on Creo, delivering revenue grow ....
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Creo Medical Group - Delivering revenue growth
Creo Medical Group Plc (CREO:LON) | 16.8 -0.1 (-2.2%) | Mkt Cap: 69.1m
- Published:
30 Jan 2026 -
Author:
Chris Donnellan -
Pages:
9 -
Creo provided a FY25 trading update with 50% revenue growth and strong operating cost containment, resulting in more than 40% reduction to the underlying operating loss. Broadly, increased adoption by new users and greater utilisation by existing users had driven revenue growth, with the company noting positive trends for the recently launched Speedboat Notch and SpydrBlade Flex device. Creo closed FY25 with cash of £12.4m. This updated supports our positive view on Creo, delivering revenue grow ....